Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc. (ACOR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
acor · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Acorda Therapeutics, Inc. (ACOR) measures how much investors pay for each dollar of the company's trailing earnings. ACOR's current PE ratio of N/A is calculated by dividing its stock price of $0.66 by its TTM earnings per share of -$203.59.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2004 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 6 fiscal years · Front-end computedMinQ1 · 25%8.7x
MedianQ3 · 75%28.1x
Max
At N/A, ACOR's current P/E is lower than in 0% of its annual fiscal year readings over the past 6 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Acorda Therapeutics, Inc.You ACOR | $1M | N/A | — | -$203.59 |
 Green Hygienics Holdings Inc. GRYN | $0M | N/A | — | -$0.20 |
 Hempacco Co., Inc. HPCO | $0M | N/A | — | -$46.95 |
 Lucy Scientific Discovery Inc. LSDI | $1M | N/A | — | -$0.71 |
 Mallinckrodt plc MNKKQ | $0M | N/A | — | -$17.48 |
 NewBridge Global Ventures, Inc. NBGV | $1M | N/A | — | — |
 Neptune Wellness Solutions Inc. NEPTF | $0M | N/A | — | -$8190.15 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-203.59 | — | |
2022-12-31 FY2022 | — | $-66.90 | — | |
2021-12-31 FY2021 | — | $-195.75 | — | |
2020-12-31 FY2020 | — | $-246.40 | — | |
2019-12-31 FY2019 | — | $-689.42 | — | |
2018-12-31 FY2018 | 3.62x | $85.98 | — | |
2017-12-31 FY2017 | — | $-583.20 | — | |
2016-12-31 FY2016 | — | $-91.79 | — | |
2015-12-31 FY2015 | 28.13x | $30.42 | +73.4% | |
2014-12-31 FY2014 | 16.22x | $50.40 | +31.4% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Acorda Therapeutics, Inc. (ACOR) measures how much investors pay for each dollar of the company's trailing earnings. ACOR's current PE ratio of N/A is calculated by dividing its stock price of $0.66 by its TTM earnings per share of -$203.59.
Frequently asked questions
ACOR pe ratio · 6 questionsACOR's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.66 and TTM EPS of -$203.59. Data sourced from Financial Modeling Prep via ACOR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Acorda Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09